Ignite Creation Date:
2024-05-05 @ 9:35 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004404
Status:
COMPLETED
Last Update Posted:
2015-03-25
First Post:
1999-10-18
Brief Title:
Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
Sponsor:
Boston Childrens Hospital
Organization:
FDA Office of Orphan Products Development
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
1998-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES
Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes
Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes
Detailed Description:
PROTOCOL OUTLINE
Patients receive oral hydroxyurea either once or twice daily plus oral clotrimazole twice daily after meals for 6 months Patients are assessed at 3 and 6 months during treatment
Completion date provided represents the completion date of the grant per OOPD records
Patients receive oral hydroxyurea either once or twice daily plus oral clotrimazole twice daily after meals for 6 months Patients are assessed at 3 and 6 months during treatment
Completion date provided represents the completion date of the grant per OOPD records
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CH-B-FDR001022 | None | None | None |
| CH-B-97-052 | None | None | None |